Clinical trial NCT02522351: Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia
Official title: Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia Due to Ischemic/Hemorrhagic Cerebral Cause (Stroke)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dysphagia
Stroke
Lead sponsor: Société des Produits Nestlé (SPN)
Sponsor class: INDUSTRY
First posted: 2015-08-13
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: The aim of the trial is to identify any systematic effect of cohesiveness on the efficacy of swallowing in patients having dysphagia problems.

Detailed description: This trial will be a double blind, randomized, crossover, controlled, and interventional trial. Each subject will test 6 study samples in a randomized order at 5 mL of volume first then at 10 mL (12 samples maximum). The trial will last a maximum of one hour (a single study visit).

The total sample size is 47 enrolled subjects, 33 subjects completed. Patients will be females and males aged between 18 and 85 years with mild proven dysphagia.

Eligibility criteria: Inclusion Criteria:

1. Mild dysphagia as defined by a score between 3 and 5 on the Dysphagia Outcome and Severity Scale
2. Patients aged between 18 and 85 years
3. Ischemic/hemorrhagic cerebral cause (stroke)
4. Able to understand French (oral and written)
5. Cognitive capacity enough to understand study procedures
6. Having health insurance (which in France is " social security")
7. Having signed the consent form.

Exclusion Criteria:

1. Any swallowing trouble not resulting from the current stroke
2. History of inhalation pneumopathy, i.e. any pulmonary inflammation linked to the path of a solid or liquid food in the respiratory system
3. Any physician diagnosed psychiatric illness
4. Patient with a digestive fistula
5. Any physician diagnosed food allergy
6. Any known allergy to barium or any compound of the contrast product
7. Confirmed or suspected perforated and occlusive syndrome
8. Pregnant or lactating women
9. Major respiratory disease needing oxygen (chronic respiratory insufficiency)
10. Subject who cannot be expected to comply with the study procedures, including consuming the test products.
11. Currently participating or having participated in another clinical trial during the month preceding the study

Primary outcomes:
measure: Identification of any systematic effect of cohesiveness on the efficacy of swallowing in dysphagic patients according to Rosenbek's Penetration-Aspiration Score (PAS) using videofluoroscopy
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
Secondary outcomes:
measure: Swallowing safety- prevalence of penetration
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing safety- prevalence of aspiration
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing function- Amount/volume of oral and pharyngeal residues
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing function- Prevalence of subjects with oral and pharyngeal residues
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing function- Oral transit time (OTT, time between tongue tip elevation and arrival of the bolus at the ramus of the mandible)
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing function- Swallow response time (SRT, time between arrival of the bolus at the ramus of the mandible and pharyngeal phases of swallowing)
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing function- Pharyngeal transit time (PTT, time between arrival of the bolus at the ramus of the mandible and the tail of the bolus passing through the upper esophageal sphincter)
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing function- Time to upper esophageal sphincter opening (UESO, time between tongue tip elevation and opening of the upper esophageal sphincter)
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing function-Time to laryngeal vestibule opening (LVO, time between tongue tip elevation and pharyngeal phases of swallowing)
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Swallowing function- Time to laryngeal vestibule closure (LVC, time between tongue tip elevation and maximal laryngeal closure)
timeFrame: During the ingestion (videofluoroscopy), maximum during one hour.
measure: Subjective perception of ease of swallowing and oropharyngeal sensation.
timeFrame: Right after ingredient ingestion, maximum during one hour.
Other outcomes:
Locations:
city: Charleroi
country: Belgium
facility: Grand hopital de Charleroi
city: Rouen
country: France
facility: Centre Hospitalier Charles Nicolle
Study officials:
References: